Insights into pathophysiology, immune response and treatment of novel CoVID-19

2021 ◽  
Vol 16 (10) ◽  
pp. 189-197
Author(s):  
Manpreet Kaur ◽  
Rajinder Kaur ◽  
Reena Gupta
Keyword(s):  
Immune Response ◽  
World Health ◽  
The Novel ◽  
Asian Countries ◽  
Human Lungs ◽  
Potential Vaccine ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Respiratory Droplets ◽  
Alveolar Edema

The beginning of year 2020 has brought with it mass destruction of mankind in form of novel coronavirus, named as CoVID-19. Declared as pandemic by World Health Organization (WHO), CoVID-19 has its origin in bats and pangolin from which it was probably transferred to human. Subsequent human to human transmission has been seen by respiratory droplets, fomites and oral-fecal route. The disease has caused widespread deaths in America, China, France and Italy followed by many European and Asian countries. CoVID-19 targets the human lungs and multiplies in alveoli using host machinery. Interstitial edema and alveolar edema at later stages cause alveoli collapse and difficulty in breathing. Severe cases may pave to systemic inflammatory response that has fatal response in body. Unfortunately, researchers are still struggling for potential vaccine or promising drug to combat the disease. WHO has issued guidelines suggesting regular hand washing, social distancing, wearing masks and quarantination as the best ways to prevent infection. This review gives an overview of the novel CoVID-19, conditions and immune response of human body related with it.

scholarly journals SARS-CoV-2 infection and the antiviral innate immune response

2020 ◽  
Author(s):  
Hui Yang ◽  
Yingying Lyu ◽  
Fajian Hou
Keyword(s):  
Immune Response ◽  
Innate Immune Response ◽  
Clinical Manifestations ◽  
Innate Immune ◽  
World Health ◽  
The Novel ◽  
Global Public Health ◽  
Replication Process ◽  
Novel Coronavirus ◽  
Health Organization

Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak began in December 2019, causing the illness known as the novel coronavirus disease 2019 (COVID-19). The virus spread rapidly worldwide to become a global public health emergency. As of 15 November 2020, more than 53 million confirmed cases and over one million deaths worldwide have been reported (World Health Organization, 2020). The SARS-CoV-2 genome was sequenced and studies are ongoing to further understand the epidemiology, clinical manifestations, etiological structure, cellular receptor angiotensin II converting enzyme (ACE2), and intracellular replication process of the virus. Currently, thousands of clinical trials related to SARS-CoV-2 are underway (https://clinicaltrials.gov/). However, no vaccines or drugs have yet been approved, until very recently, for direct treatment or prevention of COVID-19 and only supportive treatment has been applied clinically. This review will discuss the possible mechanism of the innate immune response to SARS-CoV-2 infection and provide insight into the development of related therapeutics.

scholarly journals Practices in Handling Clinical Samples in a COVID-19 Laboratory - An Experience from Chennai, India

2021 ◽  
Vol 10 (39) ◽  
pp. 3508-3510
Author(s):  
Saramma Mini Jacob ◽  
Kanagasabai Sivasangeetha ◽  
Durairaj Anitha ◽  
Singaram Kaplana
Keyword(s):  
Wide Spectrum ◽  
Clinical Manifestations ◽  
Gastrointestinal Symptoms ◽  
World Health ◽  
Clinical Samples ◽  
The Novel ◽  
Global Pandemic ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Respiratory Droplets

In early January 2020, China had started raising concerns of a new contagious disease caused by new strains of coronavirus, Severe Acute Respiratory SyndromeCoronavirus-2 (SARS-CoV-2). The World Health Organization (WHO) on March 11, 2020, had declared the novel coronavirus (COVID-19) outbreak a global pandemic. COVID-19 was transmitted from person to person through respiratory droplets generated when an infected person coughs, sneezes, breathing or through contact with a surface that has been contaminated 1 and through aerosols-airborne microdroplets.2 The clinical manifestations of COVID-19 represents a wide spectrum of disease ranging from mild to severe respiratory syndrome influenza-like illness with mainly lower respiratory tract symptoms, complicated by pneumonia and Acute Respiratory Distress Syndrome (ARDS), high fever, and headache. In many cases, loss of taste and smell and severe gastrointestinal symptoms were reported, as are cardiac problems, with the latter being perhaps secondary to a cytokine storm such as is seen in the more severely affected patients. 3 WHO COVID-19 dashboard on June 25th 2021 showed 179, 686, 071 confirmed cases worldwide.

scholarly journals Emerging Understanding of Etiology and Epidemiology of the Novel Coronavirus (COVID-19) infection in Wuhan, China

2020 ◽  
Author(s):  
Daibing Zhou ◽  
Peng Zhang ◽  
Chen Bao ◽  
Youzhi Zhang ◽  
Ning Zhu
Keyword(s):  
Respiratory Virus ◽  
Public Health Emergency ◽  
World Health ◽  
The Novel ◽  
Virus Infections ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Respiratory Virus Infections ◽  
Respiratory Droplets

The latest emergence of a novel coronavirus (COVID-19) had caused an outbreak of respiratory virus infections in Wuhan, China, and other countries so that the world health organization (WHO) declared the COVID-19 epidemic as a Public Health Emergency of International Concern (PHEIC) on January 31, 2020. At present, it is the fact that we have identified the bats as the host, the route of respiratory droplets, contact, and aerosol can accelerate the transmission from person to person. However, it is not well known about the intermediator and other approaches. Identifying and characterizing the origin and host(s) of COVID-19 can help us to evaluate the potential risk of COVID-19 for transmission among humans or cross-species.

scholarly journals Thoracic tomographic manifestations in symptomatic respiratory patients with COVID-19

2020 ◽  
Vol 53 (4) ◽  
pp. 255-261 ◽  
Author(s):  
Lucas de Pádua Gomes de Farias ◽  
Daniel Giunchetti Strabelli ◽  
Eduardo Kaiser Ururahy Nunes Fonseca ◽  
Bruna Melo Coelho Loureiro ◽  
Cesar Higa Nomura ◽  
...  
Keyword(s):  
High Sensitivity ◽  
Turnaround Time ◽  
World Health ◽  
Medical Professionals ◽  
The Novel ◽  
Asian Countries ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Sensitivity Method

Abstract China was the epicenter for the novel coronavirus disease (COVID-19), which quickly spread to other Asian countries and later to Western countries; subsequently, COVID-19 was categorized as a pandemic by the World Health Organization. Diagnosis primarily depends on viral detection in respiratory samples; however, available kits are limited, lack high sensitivity, and have a long turnaround time for providing results. In this scenario, computed tomography has emerged as an efficient and available high-sensitivity method, allowing radiologists to readily recognize findings related to COVID-19. The objective of this article is to demonstrate the main tomographic findings in symptomatic respiratory patients with COVID-19 to assist medical professionals during this critical moment.

scholarly journals Potential of CRISPR/Cas13 System in Treatment and Diagnosis of COVID-19

2021 ◽  
Author(s):  
Amir Khodavirdipour ◽  
Motahareh Piri ◽  
Sarvin Jabbari ◽  
Mohammad Khalaj-kondori
Keyword(s):  
Diagnostic Tool ◽  
Human Kidney ◽  
World Health ◽  
Rapid Review ◽  
The Novel ◽  
Rapid Action ◽  
Antiparasitic Drug ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Treatment And Diagnosis

AbstractThe novel coronavirus disease 2019 (COVID-19) belongs to coronaviridae families, like sarbecovirus (SARS), and causes pyrexia, pertussis, and acute respiratory distress syndrome (ARDS) in major. Started from Wuhan, China now forced the World Health Organization (WHO) to call it a pandemic. These dreadful figures elevate the need for rapid action for a rapid diagnostic tool, an efficacious therapy, or vaccine for such widespread disease. Here we reviewed all the latest research and trials including conventional antiviral medicines that have a narrow and finite effect on COVID-19. Recently, some advances have been made by a nucleotide/nucleoside analogues (NUC) inhibitor (remdesivir), ivermectin (antiparasitic drug), and convalescent plasma, the later one has more recently been approved by the Food and Drug Administration (FDA). In addition, a clinical-grade soluble human angiotensin-converting enzyme (ACE2), named hrsACE2, was able to inhibit the infection of human blood vessel organoids, as well as the human kidney organoids, by the virus. As of now, innovative therapeutics based on the CRISPR/Cas13d might overcome the challenge of COVID-19 either as a treatment option or precise and rapid diagnostic tool due to its rapid and precise nature. In this updated comprehensive rapid review, we try to cover all recent findings in terms of genomics, diagnosis, prevention, and treatment.

Aftermath of Covid -19 Pandemic in the community

2021 ◽  
pp. 498-500
Author(s):  
Sholly. CK
Keyword(s):  
World Health Organization ◽  
Antiviral Treatment ◽  
World Health ◽  
Health Concern ◽  
Severe Illness ◽  
Respiratory Illnesses ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Respiratory Droplets

Novel corona virus (COVID-19) is an infectious condition, which can be spread directly or indirectly from one person to another and causes respiratory illnesses, range from common cold to acute respiratory syndrome. The first cases of this virus were found in Wuhan, China. According to the World Health Organization, COVID-19 is serious health concern and has higher risk for severe illness and spreading rapidly all over the world.This novel coronavirus was named Coronavirus Disease 2019 (COVID-19) by WHO in February 2020. The World Health Organization (WHO) has declared the coronavirus disease 2019 a pandemic, in the year2020 March. A global coordinated effort is needed to stop the further spread of the virus. Among all cases about 92% of the confirmed cases were recorded from China. Initial reports suggest that death rate ranges from 1% to 2% which varies in the study and country. The most of the death have occurred in patients over 50 years of age followed by young children. For the confirmed cases which included both laboratory and clinically diagnosed till now there is no specific antiviral treatment recommended but there is vaccine currently available. Once the virus develops in people, corona viruses can be spread from person to person through respiratory droplets. The viral material hangs out in these droplets and can be breathed into the respiratory tract, where the virus can then lead to an infection. Repercussions of Covid -19 on individuals, families and on front line warriors are countless1.

scholarly journals Viability of Bacillus subtilis Cells in Airborne Bioaerosols on Face Masks

Atmosphere ◽  
2021 ◽  
Vol 12 (11) ◽  
pp. 1496
Author(s):  
Eun-Hee Lee ◽  
Yunsoo Chang ◽  
Seung-Woo Lee
Keyword(s):  
Bacillus Subtilis ◽  
World Health ◽  
The Novel ◽  
Fine Dust ◽  
Health Crisis ◽  
Viable Cells ◽  
Mask Material ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Sand Dust

The coronavirus disease 2019 (COVID-19) pandemic is a general health crisis and has irreversible impacts on human societies. Globally, all people are at risk of being exposed to the novel coronavirus through transmission of airborne bioaerosols. Public health actions, such as wearing a mask, are highly recommended to reduce the transmission of infectious diseases. The appropriate use of masks is necessary for effectively preventing the transmission of airborne bioaerosols. The World Health Organization (WHO) suggests washing fabric masks or throwing away disposable masks after they are used. However, people often use masks more than once without washing or disposing them. The prolonged use of a single mask might—as a result of the user habitually touching the mask—promote the spread of pathogens from airborne bioaerosols that have accumulated on the mask. Therefore, it is necessary to evaluate how long the living components of bioaerosols can be viable on the masks. Here, we evaluated the viability of airborne Bacillus subtilis (B. subtilis) in bioaerosols filtered on woven and anti-droplet (non-woven) face masks. As a simulation of being simultaneously exposed to sand dust and bioaerosols, the viability rates of bioaerosols that had accumulated on masks were also tested against fine dust and airborne droplets containing bacteria. The bioaerosols survived on the masks immediately after the masks were used to filter the bioaerosols, and the bacteria significantly proliferated after one day of storage. Thereafter, the number of viable cells in the filtered bioaerosols gradually decreased over time, and the viability of B. subtilis in bioaerosols on the masks varied, depending on the mask material used (woven or non-woven). Despite the reduction in viability, bioaerosols containing living components were still found in both woven and anti-droplet masks even after six days of storage and it took nine days not to have found them on masks. The number of viable cells in bioaerosols on masks significantly decreased upon exposure of the masks to fine dust. The results of this study should provide useful information on how to appropriately use masks to increase their duration of effectiveness against bioaerosols.

scholarly journals A Bittersweet Memoir

2021 ◽  
Vol 16 (1) ◽  
pp. 128-135
Author(s):  
Anita Y. N. Lim
Keyword(s):  
Video Clip ◽  
Early Period ◽  
General Medicine ◽  
University Hospital ◽  
World Health ◽  
Public Healthcare ◽  
The Novel ◽  
National University ◽  
Novel Coronavirus ◽  
Health Organization

Abstract I wrote this journal in March 2020 prior to the World Health Organization declaring the COVID-19 infection as a worldwide pandemic on March 11. The situation in Singapore was unfolding even as public healthcare institutions were tasked to lead the charge to contain the novel coronavirus as it was then called. This journal describes my experiences and impressions during my work in an isolation ward at the National University Hospital during this early period. I was to be catapulted into Pandemic Team 3 in the second and third weeks of February 2020. The urgency of hospital measures to respond to the novel coronavirus meant that the general medicine consultant roster which I was on was hijacked to support the pandemic wards. I thought wryly to myself that it was a stroke of genius to commandeer the ready-made roster of senior physicians; it would have been difficult for the roster monster to solicit senior physicians to volunteer when there were still so many unknowns about this virus. Graphic images of the dire situation in Wuhan, China, were circulating widely on social media. It was heart-wrenching to read of Dr. Li Wen Liang’s death. He had highlighted the mysterious pneumonia-causing virus. The video clip of him singing at a karaoke session that went viral underscored the tragedy of a young life cut short. Questions raced in my mind. “Are we helpless to prevent the spread of this virus?” “Is the situation in China to be replicated here in Singapore?” This seemed incredulous, yet, might it be possible? The immediate responses that jumped up within me was “yes, it’s possible, but let’s pray not. Whatever has to be done, must be done.”

scholarly journals Cutaneous presentation of COVID-19 Case Report

2020 ◽  
Vol 3 (3) ◽  
pp. 01-02
Author(s):  
Khadiga Ismail
Keyword(s):  
Public Health Emergency ◽  
World Health ◽  
The Novel ◽  
Scientific Journals ◽  
Global Public Health ◽  
The World ◽  
Global Spread ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Recent Attention

COVID-19 has high transmissibility and infectivity among human. On January 30, 2020, the World Health Organization (WHO) in an effort to slow down the global spread of the virus declared the outbreak, “A global public health emergency of international concern". The skin manifestations of the novel coronavirus COVID-19 were not recognized at the early stages of the pandemic but have received much recent attention in scientific journals. Reported manifestations range from pseudo-chilblains to a morbilliform (measles-like) exanthem, urticaria, vesicular eruptions, a dengue-like petechial rash and ovate scaling macules, and plaques mimicking pityriasis rosea.

A Qualitative Comparison of the Covex Respirator with Face Shield Versus the N95 Respirator

2020 ◽  
Author(s):  
Reid Mimmack ◽  
Elijah Germo ◽  
Garrett Augustine ◽  
Kumar Belani
Keyword(s):  
Filtration Efficiency ◽  
Current Medical ◽  
Pass Rate ◽  
World Health ◽  
Protective Equipment ◽  
The Novel ◽  
Qualitative Comparison ◽  
Medical Standard ◽  
Novel Coronavirus ◽  
Health Organization

Abstract In March 2020, the World Health Organization declared the novel coronavirus (COVID-19) outbreak a worldwide pandemic. The pandemic led to concerns of shortages regarding healthcare-related resources, including personal protective equipment (PPE), ventilators, and more. The uniquely designed COVEX respirator with face shield was engineered and manufactured by Augustine Surgical, Inc. to combat the PPE shortage. The novel COVEX mask is an “all-in-one” face shield and filter with a Viral Filtration Efficiency (VFE) greater than 99%. A standard respirator qualitative fit test was completed on the COVEX respirator as well as the current medical standard 3M N95 respirator. Fit test studies comparing the two masks yielded similar outcomes. The COVEX respirator had a qualitative fit test pass rate of 96.6% and the 3M N95 respirator had a pass rate of 93.3% (n=30). Participants also reported other variables comparing the comfort and fit of each mask, which is described further in the discussion. The COVEX respirator with face shield passed a standardized qualitative fit test at a rate similar to the current medical standard N95 respirator. Our results suggest that the COVEX mask may be a viable PPE option in the future.

Sign in / Sign up

Export Citation Format

Share Document